Literature DB >> 15509646

Hemorrhagic pheochromocytoma associated with systemic corticosteroid therapy and presenting as myocardial infarction with severe hypertension.

Hilary Brown1, Philip A Goldberg, Jared G Selter, Henry S Cabin, Norman J Marieb, Robert Udelsman, John F Setaro.   

Abstract

Pheochromocytomas classically present with paroxysms of hypertension and adrenergic symptoms including headaches, palpitations, tremor, and anxiety. However, these tumors can be clinically silent and occasionally present only when catecholamine release is up-regulated by exogenous stimuli. In addition, the clinical presentation of pheochromocytoma can mimic a number of more common medical conditions, including migraine headaches, cardiac arrhythmias, and myocardial infarction, making diagnosis difficult. In this report, we present the case of a young woman who, while receiving oral corticosteroid therapy for presumed migraine headaches, suffered a myocardial infarction and ultimately hemorrhaged into a previously undiagnosed pheochromocytoma. Our patient exhibited severe, labile hypertension after the administration of iv beta-blockade for presumed myocardial ischemia, raising our initial clinical suspicion for pheochromocytoma. In this paper we review some of the key clinical issues related to this complex case, including steroid-induced stimulation of catecholamine synthesis and release, the role of pheochromocytoma in myocardial ischemia and electrocardiographic changes, and the rare complication of tumor hemorrhage. We then briefly review the essential diagnostic and management strategies for this rare but potentially lethal tumor, with specific emphasis on pheochromocytoma-related cardiovascular emergencies and the surgical management of tumor hemorrhage.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15509646     DOI: 10.1210/jc.2004-1077

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Endomyocardial biopsy in a patient with hemorrhagic pheochromocytoma presenting as inverted Takotsubo cardiomyopathy.

Authors:  Kohei Iio; Shunpei Sakurai; Tamon Kato; Shigeki Nishiyama; Takeki Hata; Eiichiro Mawatari; Chihiro Suzuki; Kazuhiro Takekoshi; Kayoko Higuchi; Toru Aizawa; Uichi Ikeda
Journal:  Heart Vessels       Date:  2012-04-05       Impact factor: 2.037

Review 2.  Pheochromocytoma crisis after a dexamethasone suppression test for adrenal incidentaloma.

Authors:  Dong Won Yi; Sun Young Kim; Dong Hoon Shin; Yang Ho Kang; Seok Man Son
Journal:  Endocrine       Date:  2010-01-05       Impact factor: 3.633

3.  Clinical characteristics and outcomes of pheochromocytoma crisis: a literature review of 200 cases.

Authors:  Y Ando; Y Ono; A Sano; N Fujita; S Ono; Y Tanaka
Journal:  J Endocrinol Invest       Date:  2022-07-20       Impact factor: 5.467

Review 4.  Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management.

Authors:  Graeme Eisenhofer; Graham Rivers; Alejandro L Rosas; Zena Quezado; William M Manger; Karel Pacak
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

5.  Pheochromocytoma crisis with cyclic fluctuation in blood pressure mimics acute coronary syndrome.

Authors:  Mitsuhiro Kometani; Takashi Yoneda; Yuji Maeda; Masashi Oe; Yoshimichi Takeda; Takuya Higashitani; Daisuke Aono; Asuka Yoshino; Shigehiro Karashima; Yoshiyu Takeda
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2020-09-23

6.  Pheochromocytoma Mimicking Acute Coronary Syndrome: A Case Report.

Authors:  Yanwei Cheng; Lijie Qin; Long Chen
Journal:  Front Oncol       Date:  2022-04-13       Impact factor: 5.738

7.  Pheochromocytoma presenting with myocardial infarction, cardiomyopathy, renal failure, pulmonary hemorrhage, and cyclic hypotension: case report and review of unusual presentations of pheochromocytoma.

Authors:  Meyeon Park; Katarzyna Hryniewicz; John F Setaro
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-02       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.